Rosenthal SA, et al. - Between 2005 and 2009, researchers estimated the outcome of docetaxel chemotherapy (CT) on overall survival (OS) and clinical consequences among subjects with high-risk prostate cancer in this multicenter randomized NRG Oncology RTOG 0521 study. They observed 15.1 ng/mL, a median prostate-specific antigen with a Gleason scores 9 to 10 cancer among 53% of cases whereas 27% had cT3 to cT4 disease. They noted an improvement in OS from 89% to 93% at 4 years with improved disease-free survival and reduction in the rate of distant metastasis for candidates with high-risk nonmetastatic prostate cancer, CT with docetaxel. Hence, they suggested docetaxel CT an option of the regimen for men with high-risk prostate cancer.